Results 151 to 160 of about 24,552 (280)

Comparison of Venetoclax‐Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single‐Center Real‐World Experience

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction The optimal venetoclax‐based treatment for patients with relapsed/refractory (R/R) CLL is still unknown, especially for high‐risk patients. Methods We performed a retrospective analysis of 98 patients with R/R CLL treated with venetoclax‐based regimens.
Benjamin Heyman, Michael Choi, Thomas J. Kipps   +2 more
wiley   +1 more source

Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies [PDF]

Andrés Bravo-González, Maryam Alasfour, Deborah Soong, Jose Noy, Georgios Pongas   +4 more
openalex   +1 more source

Treatment Outcomes and Overall Survival of Patients With B‐Cell Prolymphocytic Leukemia

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction B‐cell prolymphocytic leukemia (B‐PLL) is a rare, aggressive leukemic B‐cell malignancy historically associated with poor outcomes and recently reclassified in the WHO Fifth Edition but retained as a distinct entity in the ICC.
Daniel A. Ermann, Victoria A. Vardell, Lindsey Fitzgerald, Allison Bock, Harsh Shah, Boyu Hu, Deborah M. Stephens   +6 more
wiley   +1 more source

The Immunologic Paradox of BTK Inhibitors in Chronic Lymphocytic Leukemia: Selectivity, Hypogammaglobulinemia, and Infection Risk. [PDF]

Cancers (Basel)
Andreescu M, Tudorache SI, Moldovan CA, Moldovan AD, Cochior D, Popov V, Andreescu B, Ionescu D, Padurariu-Covit MD.   +8 more
europepmc   +1 more source

Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK) [PDF]

, 2019
Scott H. Watterson, Qingjie Liu, Myra Beaudoin Bertrand, Douglas G. Batt, Ling Li, Mark A. Pattoli, Stacey Skala, Lihong Cheng, Mary T. Obermeier, Robin Moore, Zheng Yang, Rodney Vickery, Paul A. Elzinga, Lorell Discenza, Celia D’Arienzo, Kathleen M. Gillooly, Tracy Taylor, Claudine Pulicicchio, Yifan Zhang, Elizabeth Heimrich, Kim W. McIntyre, Qian Ruan, Richard A. Westhouse, Ian M. Catlett, Naiyu Zheng, Charu Chaudhry, Jun Dai, Michael A. Galella, Andrew J. Tebben, Matt Pokross, Jianqing Li, Rulin Zhao, Daniel Smith, Richard Rampulla, Alban J. Allentoff, Michael A. Wallace, Arvind Mathur, Luisa Salter–Cid, John E. Macor, Percy H. Carter, Aberra Fura, James R. Burke, Joseph A. Tino   +42 more
openalex   +1 more source

Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real‐World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T‐Cell Era

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background Allogeneic hematopoietic cell transplantation (alloHCT) remains a curative option for relapsed or refractory (r/r) mantle cell lymphoma (MCL), although its role has shifted in the era of Bruton tyrosine kinase inhibition (BTKi) and chimeric antigen receptor T‐cell (CAR‐T) therapy.
Enver Aydilek, Paolo Mazzeo, Justin Hasenkamp, Markus Maulhardt, Tobias Tix, Evgenii Shumilov, Gerald Wulf   +6 more
wiley   +1 more source

Atypical X-linked agammaglobulinemia diagnosed in adulthood with arthritis caused by a hypomorphic BTK splice-site variant: a case report and literature review. [PDF]

Front Immunol
Takayama A, Meguro K, Yokota M, Sugiyama T, Kurihara S, Hiraguri M, Kanegane H, Nakajima H.   +7 more
europepmc   +1 more source

Prognostic value of MYD88/CXCR4 mutation allele fraction in Waldenström macroglobulinemia using a multiplex ddPCR assay

HemaSphere, Volume 10, Issue 6, June 2026.
Eleni Thanou, Ioannis Kollias, Eleni Kalafati, Christos Vlachos, Nefeli Mavrianou‐Koutsoukou, Ourania Theologi, Maria Sakkou, Christine Liacos, Konstantina Taouxi, Alexandra Papadimou, Katerina Chrisostomidou, Agisilaos Papadopoulos, Maria Gavriatopoulou, Evangelos Terpos, Evi Lianidou, Meletios A. Dimopoulos, Efstathios Kastritis, Athina Markou, Tina Bagratuni   +18 more
wiley   +1 more source

BCMA CAR T for AL Amyloidosis After Plasmacytic Relapse of Lymphoplasmacytic Lymphoma

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Lambda immunoglobulin light chain (AL) amyloidosis associated with non‐IgM lymphoplasmacytic lymphoma (LPL) is rare and often refractory to conventional therapies. Treatment options for relapsed disease remain limited. Methods Here we describe the case of a patient with a history of LPL‐associated AL amyloidosis who had previously
Nadia Al Haddad, Eugene Brailovski, Jacqueline Dela‐Pena, Melinda Cook, Michael Rosenzweig, Heather Jolie Landau   +5 more
wiley   +1 more source

Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies. [PDF]

Int J Mol Sci
Meza K, Barrientos Risso C, Shah A, Romagnoli C, Sandoval J, Brauchle Y, Lyubimova A, Santos L, Goya Balaguer E, Barrientos J.   +9 more
europepmc   +1 more source